Blocknomi
TLDR Tozorakimab achieved its primary goal in AstraZeneca’s Phase III MIRANDA study for chronic obstructive pulmonary disease The investigational therapy demonstrated significant reduction in moderate-to-severe exacerbations compared to placebo in…
Related articles
-
Mastercard Weighs RLUSD Settlement On XRP Ledger, Exec Says
Bitcoinist Published 18.04.2026 05:00
-
Bitcoin daily gains near 3% as stocks ignore US-Iran war threat, oil drops
Cointelegraph Published 20.04.2026 15:14
-
Quantum Computers Could Boost AI by Processing Large Datasets More Efficiently
Decrypt Published 21.04.2026 17:18
-
Ethereum Faces Liquidity Pressure as Price Swings Between $2,200 and $2,500 Zones
Blocknomi Published 19.04.2026 22:58
-
Morning Crypto Report — XRP Scores Best ETF Week Since February With $11.75 Million, Bitcoin Fails $74,000 Breakout Ahead of Tuesday's April 14 PPI Data, Shiba Inu (SHIB) Coils for 33% Move as Volatility Hits Rare Lows
U.Today Published 12.04.2026 13:41
-
Ledger Recover Explained: How It Preserves Security While Adding a Recovery Option
BlockchainReporter Published 15.04.2026 12:21
-
Major New Aave Crypto Proposal Passes: Everything Just Changed For Aave Price Prediction in 2026 – Here’s Why
Cryptonews Published 13.04.2026 11:39
-
ARK Invest Loads Up on Amazon (AMZN) Stock Ahead of Earnings, Exits Iridium Position
Blocknomi Published 21.04.2026 11:34